[1]
2024. Efficacy and safety of bevacizumab in neoadjuvant and concurrent chemoradiotherapy for refractory cervical cancer patients. Biomolecules and Biomedicine. 24, 6 (Oct. 2024), 1586–1594. DOI:https://doi.org/10.17305/bb.2024.10528.